Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Clovis Oncology Inc CLVSQ

Healthcare Biotechnology
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (PINL:CLVSQ)

Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286

Business Wire December 12, 2022

Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat

Business Wire October 27, 2022

Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Business Wire October 17, 2022

TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations

Business Wire October 3, 2022

Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement

Business Wire September 21, 2022

Clovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian Cancer

Business Wire September 13, 2022

Clovis Oncology's Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Business Wire September 11, 2022

Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs

Business Wire August 8, 2022

Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8

Business Wire July 20, 2022
View More News ››

Opinion & Analysis (PINL:CLVSQ)

Use stock volatility to invest in innovative oncology companies: JMP Security's Michael King Jr.

Gail Dutton October 15, 2015
View More Opinion ››

Bullboard Posts (PINL:CLVSQ)

no brainer.

Just scooped up 560!!!! 
aabrahadabraa - February 9, 2021

Very good pick

I bought it at $6. And I m so proud of my decision for holding it.
Chartsmart99 - January 27, 2021

Targeted Therapy - Opportunity to Ditch Chemo?

PARP inhibitors - Clovis, Astra Zeneca, Tesaro, more at:   https://www.channelchek.com/news-channel/An_Opportunity_to_Ditch...
schoolofrock - September 4, 2020

it's a buy today for me

got it at $9.59 per share,so glta.
coolfooldumbguy - January 17, 2020

FYI (Seeking Alpha) Bret Jensen

1. The dividend is hiked in the 1st half of 2017: This is pretty much a no-brainer as the company has stated it will be less focused...
Carlos66 - January 11, 2017

Top gainers of Healthcare Sector stocks: CLVS, CRME, ACRX

HealthCare sector showed uptrend on Thursday and in this article we discuss top gainers of HealthCare sectors and disclose their news...
wsnews4investor - May 15, 2015
View more Bullboard ››

Tribe Property Technologies Inc.

Tribe Property Technologies Inc.

Tribe Property Technologies Inc. is a property technology company. The Company offers technology-enabled property management ...
View More »